List volumes - List articles in this issue

Investigative Report

Psoriasis and Hypertension: A Case-Control Study

doi: 10.2340/00015555-0741


In recent years, numerous reports have demonstrated an association between psoriasis and metabolic syndrome. However, some studies failed to demonstrate an association between psoriasis and hypertension. The aim of the present study was to examine the association be­tween psoriasis and hypertension. Psoriasis patients of a health-maintenance organization were compared with enrollees without psoriasis regarding the prevalence of hypertension in a case-control study. The study included 12,502 psoriasis patients over the age of 20 years and 24,285 age- and sex-frequency-matched controls. The prevalence of hypertension was significantly higher in psoriasis patients than controls (38.8%, 29.1%, respectively, p < 0.001). In a multivariate analysis, hypertension was associated with psoriasis after controlling for age, sex, smoking status, obesity, diabetes, non-steroidal anti-inflammatory drugs (NSAIDs) and use of Cox-2 inhibitors (odds ratio: 1.37, 95% confidence interval: 1.29–1.46). The results of this study support the previously noted association between psoriasis and hypertension. We suggest that patients with psoriasis should be routinely screened for the presence of hypertension.


Arnon D. Cohen, Dahlia Weitzman and Jacob Dreiher


  • Naldi L, Chatenoud L, Belloni A, Peserico A, Balato N, Virgili AR, et al. Medical history, drug exposure and the risk of psoriasis. Evidence from an Italian case-control study. Dermatology 2008; 216: 125–130.
  • Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A,Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61–67.
  • Naldi L, Peli L, Parazzini F. Association of early-stage psoriasis with smoking and male alcohol consumption: evidence from an Italian case-control study. Arch Dermatol 1999; 135: 1479–1484.
  • Naldi L, Peli L, Parazzini F, Carrell CF, Psoriasis Study Group of the Italian Group for Epidemiological Research in Dermatology. Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. J Am Acad Dermatol 2001; 44: 433–438.
  • Malerba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, et al. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006; 155: 1165–1169.
  • Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007; 87: 506–509.
  • Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152–155.
  • Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735–1741.
  • Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68–73.
  • Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982–986.
  • Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143: 1559–1565.
  • Inerot A, Enerback C, Enlund F, Martinsson T, Samuelsson L, Wahlström J. et al. Collecting a set of psoriasis family material through a patient organisation; clinical characterisation and presence of additional disorders. BMC Dermatol 2005; 5: 10.
  • Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol 2007; 57: 347–354.
  • Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986; 172: 298–304.
  • Lindegard B. Mortality and causes of death among psoriatics. Dermatologica 1989; 179: 91–92.
  • Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829–835.
  • Pearce DJ, Morrison AE, Higgins KB, Crane MM, Balkrishnan R, FleischerAB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005; 16: 319–323.
  • Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007; 56: 629–634.
  • Sommer DM, Jenisch S, Suchan M, Christophers E, Weichental M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321–328.
  • Alberti KG, Zimmet P. The metabolic syndrome: time to reflect. Curr Diab Rep 2006; 6: 259–261.
  • Alberti KG, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 1059–1062.
  • Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469–480.
  • Timar O, Sestier F, Levy E. Metabolic syndrome X: a review. Can J Cardiol 2000; 16: 779–789.
  • Zambon A, Pauletto P, Crepaldi G. Review article: the metabolic syndrome – a chronic cardiovascular inflammatory condition. Aliment Pharmacol Ther 2005; 22 Suppl 2: 20–23.
  • Bowcock AM. Understanding the pathogenesis of psoriasis, psoriatic arthritis, and autoimmunity via a fusion of molecular genetics and immunology. Immunol Res 2005; 32: 45–56.
  • Rennert G, Peterburg Y. Prevalence of selected chronic diseases in Israel. Isr Med Assoc J 2001; 3: 404–408.
  • Phillips MI, Kagiyama S. Angiotensin II as a pro-inflammatory mediator. Curr Opin Investig Drugs 2002; 3: 569–577.
  • Huskic J, Alendar F. Tissue angiotensin-converting enzyme in patients with various clinical forms of psoriasis. Bosn J Basic Med Sci 2007; 7: 103–106.
  • Ryder KW, Epinette WW, Jay SJ, Ransburg Rc, Glick MR. Serum angiotensin converting enzyme activity in patients with psoriasis. Clin Chim Acta 1985; 153: 143–146.
  • Ena P, Madeddu P, Glorioso N, Cerimele D, Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol 1985; 40: 199–205.
  • Bonifati C, Mussi A, Carducci M, D’auria L, Ameglio F. Endothelin-1 levels are increased in sera and lesional skin extracts of psoriatic patients and correlate with disease severity. Acta Derm Venereol 1998; 78: 22–26.
  • Sowers JR. Hypertension, angiotensin II, and oxidative stress. N Engl J Med 2002; 346: 1999–2001.
  • Berkson J. Limitations of the application of four-fold table analysis to hospital data. Biometrics 1946; 2: 47–53.
  • Related articles

    There are no related articles.

    Share with your friends



    Full text



    There is no supplementary for this article.

    Print information

    Volume 90, Issue 1

    DOI: 10.2340/00015555-0741

    Pages: 23-26

    View at PubMed